This technology is a kinase inhibitor that directly targets oncogenes for the pharmacological treatment of lymphomas.
The proto-oncogene c-Myc can contribute to lymphoma pathogenesis. While downregulation of c-Myc may be an effective method for treatment of lymphomas, direct inhibition has proven difficult. It has previously been shown that inhibition of casein kinase 1 epsilon (CK1ε) results in decreased c-Myc expression and reduced viability of lymphoma cells. Thus, targeting CK1ε may be an effective therapeutic strategy for treatment of lymphomas.
This technology identifies a potential therapeutic compound that efficiently downregulates c-Myc expression via inhibition of CK1ε. This compound, CUX-0404A, is a more active analogue of umbralisib, a known CK1ε inhibitor. Preliminary data suggest that CUX-0404A potently inhibits the translation of c-Myc, resulting in decreased lymphoma cell viability. Thus, this technology has the potential to be used either by itself or in conjunction with other therapies for more effective treatment of lymphomas. Although c-Myc has been identified as an oncogene that plays a critical role in lymphoma pathogenesis, direct inhibition of c-Myc has long proven to be difficult.
This technology has been validated in lymphoma, leukemia, and myeloma cell lines and primary lymphoma and leukemia cells
IR CU18217
Licensing Contact: Jerry Kokoshka